Brought to you by 
Forest gets small-molecule pain candidates from Grunenthal; GRT6005/cebranopadol part ended
27 Oct 2020
Executive Summary
In their second partnership, Grunenthal GMBH (mid-sized European drug company focused on pain management) has licensed Forest Laboratories Inc. exclusive US and Canadian rights to its pain compounds GRT6005 (cebranopadol) and GRT6006 (lexanopadol). Forest also received a European co-promotion option.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest gets small-molecule pain candidates from Grunenthal; GRT6005/cebranopadol part ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice